{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:37:51Z","timestamp":1762573071842,"version":"build-2065373602"},"reference-count":20,"publisher":"Japan Endocrine Society","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2025]]},"DOI":"10.1507\/endocrj.ej25-0159","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T22:07:22Z","timestamp":1754345242000},"page":"1197-1204","source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness of evocalcet for hypercalcemia in patients with primary hyperparathyroidism"],"prefix":"10.1507","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3538-3163","authenticated-orcid":false,"given":"Kenichi","family":"Tanaka","sequence":"first","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"},{"name":"Department of Rheumatology and Diabetes, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Okada","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"},{"name":"Clinical Research Center, Hospital of the University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Koikawa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumi","family":"Uemura","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maiko","family":"Sumikawa","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichi","family":"Torimoto","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0807-7139","authenticated-orcid":false,"given":"Yoshiya","family":"Tanaka","sequence":"additional","affiliation":[{"name":"First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Peschke E, M\u00fchlbauer E (2010) New evidence for a role of melatonin in glucose regulation. Best Pract Res Clin Endocrinol Metab 24: 829\u2013841.","DOI":"10.1016\/j.beem.2010.09.001"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Pallan S, Rahman MO, Khan AA (2012) Diagnosis and management of primary hyperparathyroidism. BMJ 344: e1013.","DOI":"10.1136\/bmj.e1013"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Rubin MR, Bilezikian JP, McMahon DJ, Jacobs T, Shane E, et al. (2008) The natural history of primary hyperparathyroidism with or without parathyroid surgery after 15 years. J Clin Endocrinol Metab 93: 3462\u20133470.","DOI":"10.1210\/jc.2007-1215"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Takeuchi Y, Takahashi S, Miura D, Katagiri M, Nakashima N, et al. (2017) Cinacalcet hydrochloride relieves hypercalcemia in Japanese patients with parathyroid cancer and intractable primary hyperparathyroidism. J Bone Miner Metab 35: 616\u2013622.","DOI":"10.1007\/s00774-016-0797-0"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Dong BJ (2005) Cinacalcet: an oral calcimimetic agent for the management of hyperparathyroidism. Clin Ther 27: 1725\u20131751.","DOI":"10.1016\/j.clinthera.2005.11.015"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, et al. (2011) Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab 96: E9\u2013E18.","DOI":"10.1210\/jc.2010-1221"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Palmer SC, Nistor I, Craig JC, Pellegrini F, Messa P, et al. (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10: e1001436.","DOI":"10.1371\/journal.pmed.1001436"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Kawata T, Tokunaga S, Murai M, Masuda N, Haruyama W, et al. (2018) A novel calcimimetic agent, evocalcet (MT-4580\/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes <i>in vivo<\/i> and <i>in vitro<\/i>. PLoS One 13: e0195316.","DOI":"10.1371\/journal.pone.0195316"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Takeuchi Y, Nishida Y, Kondo Y, Imanishi Y, Fukumoto S (2020) Evocalcet in patients with primary hyperparathyroidism: an open-label, single-arm, multicenter, 52-week, dose-titration phase III study. J Bone Miner Metab 38: 687\u2013694.","DOI":"10.1007\/s00774-020-01097-y"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ng CH, Chin YH, Tan MHQ, Ng JX, Yang SP, et al. (2020) Cinacalcet and primary hyperparathyroidism: systematic review and meta regression. Endocr Connect 9: 724\u2013735.","DOI":"10.1530\/EC-20-0221"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Soen S, Fukunaga M, Sugimoto T, Sone T, Fujiwara S, et al. (2013) Diagnostic criteria for primary osteoporosis: year 2012 revision. J Bone Miner Metab 31: 247\u2013257.","DOI":"10.1007\/s00774-013-0447-8"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Khosla S, Melton LJ 3rd, Wermers RA, Crowson CS, O\u2019Fallon W, et al. (1999) Primary hyperparathyroidism and the risk of fracture: a population-based study. J Bone Miner Res 14: 1700\u20131707.","DOI":"10.1359\/jbmr.1999.14.10.1700"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Silverberg SJ, Shane E, de la Cruz L, Dempster DW, Feldman F, et al. (1989) Skeletal disease in primary hyperparathyroidism. J Bone Miner Res 4: 283\u2013291.","DOI":"10.1002\/jbmr.5650040302"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Peacock M, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, et al. (2009) Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J Clin Endocrinol Metab 94: 4860\u20134867.","DOI":"10.1210\/jc.2009-1472"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Manaka K, Sato J, Kinoshita Y, Ito N, Fujita M, et al. (2019) Effectiveness and safety of cinacalcet for primary hyperparathyroidism: a single center experience. Endocr J 66: 683\u2013689.","DOI":"10.1507\/endocrj.EJ19-0034"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9: 310\u2013322.","DOI":"10.2174\/138920008784220664"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Narushima K, Maeda H, Shiramoto M, Endo Y, Ohtsuka S, et al. (2019) Assessment of CYP-mediated drug interactions for evocalcet, a new calcimimetic agent, based on <i>in vitro<\/i> investigations and a cocktail study in humans. Clin Transl Sci 12: 20\u201327.","DOI":"10.1111\/cts.12588"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Fukagawa M, Shimazaki R, Akizawa T (2018) Head-to-head comparison of the new calcimimetic agent evocalcet with cinacalcet in Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 94: 818\u2013825.","DOI":"10.1016\/j.kint.2018.05.013"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, et al. (2022) The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials. J Bone Miner Res 37: 2351\u20132372.","DOI":"10.1002\/jbmr.4685"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Bilezikian JP, Khan AA, Silverberg SJ, Fuleihan GE, Marcocci C, et al. (2022) Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J Bone Miner Res 37: 2293\u20132314.","DOI":"10.1002\/jbmr.4677"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/11\/72_EJ25-0159\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T03:33:26Z","timestamp":1762572806000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/72\/11\/72_EJ25-0159\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":20,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej25-0159","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"type":"print","value":"0918-8959"},{"type":"electronic","value":"1348-4540"}],"subject":[],"published":{"date-parts":[[2025]]},"article-number":"EJ25-0159"}}